These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27406745)

  • 21. Immune Modulation of Metastatic Niche Formation in the Bone.
    Cheng X; Wang Z
    Front Immunol; 2021; 12():765994. PubMed ID: 34745140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation.
    Persaud SP; Ritchey JK; Kim S; Lim S; Ruminski PG; Cooper ML; Rettig MP; Choi J; DiPersio JF
    J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34730109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple-negative breast cancer cells rely on kinase-independent functions of CDK8 to evade NK-cell-mediated tumor surveillance.
    Knab VM; Gotthardt D; Klein K; Grausenburger R; Heller G; Menzl I; Prinz D; Trifinopoulos J; List J; Fux D; Witalisz-Siepracka A; Sexl V
    Cell Death Dis; 2021 Oct; 12(11):991. PubMed ID: 34689158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lanatoside C inhibits human cervical cancer cell proliferation and induces cell apoptosis by a reduction of the JAK2/STAT6/SOCS2 signaling pathway.
    Duan Y; Chen L; Shao J; Jiang C; Zhao Y; Li Y; Ke H; Zhang R; Zhu J; Yu M
    Oncol Lett; 2021 Oct; 22(4):740. PubMed ID: 34466152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteoimmuno-Oncology: Therapeutic Opportunities for Targeting Immune Cells in Bone Metastasis.
    Kähkönen TE; Halleen JM; Bernoulli J
    Cells; 2021 Jun; 10(6):. PubMed ID: 34204474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Different JAK Inhibitors and Methotrexate on Lymphocyte Proliferation and DNA Damage.
    Reddig A; Voss L; Guttek K; Roggenbuck D; Feist E; Reinhold D
    J Clin Med; 2021 Apr; 10(7):. PubMed ID: 33916057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcription Factors Associated With IL-15 Cytokine Signaling During NK Cell Development.
    Wang X; Zhao XY
    Front Immunol; 2021; 12():610789. PubMed ID: 33815365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological bases of cancer immunotherapy.
    Gonzales Carazas MM; Pinto JA; Casado FL
    Expert Rev Mol Med; 2021 Mar; 23():e3. PubMed ID: 33762030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opioids drive breast cancer metastasis through the δ-opioid receptor and oncogenic STAT3.
    Tripolt S; Neubauer HA; Knab VM; Elmer DP; Aberger F; Moriggl R; Fux DA
    Neoplasia; 2021 Feb; 23(2):270-279. PubMed ID: 33465556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response.
    von Locquenghien M; Rozalén C; Celià-Terrassa T
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33393507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of the JAK/STAT Pathway in Cervical Cancer: Its Relationship with HPV E6/E7 Oncoproteins.
    Gutiérrez-Hoya A; Soto-Cruz I
    Cells; 2020 Oct; 9(10):. PubMed ID: 33076315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. STAT3: Versatile Functions in Non-Small Cell Lung Cancer.
    Mohrherr J; Uras IZ; Moll HP; Casanova E
    Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted Therapies: Friends or Foes for Patient's NK Cell-Mediated Tumor Immune-Surveillance?
    Damele L; Ottonello S; Mingari MC; Pietra G; Vitale C
    Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32218226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What Is the Role of Interleukins in Breast Cancer Bone Metastases? A Systematic Review of Preclinical and Clinical Evidence.
    Salamanna F; Borsari V; Contartese D; Costa V; Giavaresi G; Fini M
    Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31847214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation.
    Gotthardt D; Trifinopoulos J; Sexl V; Putz EM
    Front Immunol; 2019; 10():2590. PubMed ID: 31781102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma.
    Kim SJ; Yoon DH; Kang HJ; Hong JY; Lee HS; Oh SY; Shin HJ; Kong JH; Yi JH; Sakamoto K; Ko YH; Huh J; Lee SS; Takeuchi K; Shin DY; Suh C; Kim WS
    BMC Cancer; 2019 Nov; 19(1):1080. PubMed ID: 31707975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. STAT5A and STAT5B-Twins with Different Personalities in Hematopoiesis and Leukemia.
    Maurer B; Kollmann S; Pickem J; Hoelbl-Kovacic A; Sexl V
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31690038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Balancing STAT Activity as a Therapeutic Strategy.
    Polak KL; Chernosky NM; Smigiel JM; Tamagno I; Jackson MW
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31684144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.
    Nakamura K; Smyth MJ
    Cell Mol Immunol; 2020 Jan; 17(1):1-12. PubMed ID: 31611651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression.
    Mohrherr J; Haber M; Breitenecker K; Aigner P; Moritsch S; Voronin V; Eferl R; Moriggl R; Stoiber D; Győrffy B; Brcic L; László V; Döme B; Moldvay J; Dezső K; Bilban M; Popper H; Moll HP; Casanova E
    Int J Cancer; 2019 Dec; 145(12):3376-3388. PubMed ID: 31407334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.